U.S., Aug. 23 -- ClinicalTrials.gov registry received information related to the study (NCT07137312) titled 'Ex Vivo Expansion (ACT-X)' on Aug. 15.
Brief Summary: The purpose of this study is to understand how the body's immune cells respond to a new type of vaccine (neoantigen vaccine) designed to help the immune system recognize and fight cancer. To do this, the study team will collect a research specimen from participants to study their immune cells' reactions to the neoantigen vaccine. This research will help researchers learn more about how these vaccines might work to protect or treat against cancer.
Study Start Date: Oct., 2025
Study Type: OBSERVATIONAL
Condition:
Solid Tumor
Healthy
Intervention:
PROCEDURE: Blood Draw
Partic...